Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.79 USD
+0.51 (1.49%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $34.77 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Therapeutics (CORT) Q1 Earnings Top Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Rides High on Cushing's Syndrome Drug Korlym
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. The company's efforts to expand the drug's label also hold promise and bode well for long-term growth.
Corcept (CORT) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Corcept (CORT) earnings beat estimates in the fourth quarter of 2018 on increased revenues.
Options Traders Expect Huge Moves in Corcept (CORT) Stock
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Corcept (CORT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Up 13.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Initiates Phase III Study for Cushing's Syndrome
by Zacks Equity Research
Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome.
Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept (CORT) reports in-line earnings in the third quarter of 2018 and reaffirms its revenue guidance for 2018.
Corcept Therapeutics (CORT) Meets Q3 Earnings Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
Corcept Therapeutics (CORT) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -16.67% and -9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock
by Zacks Equity Research
Investors in Corcept Therapeutics (CORT) need to pay close attention to the stock based on moves in the options market lately.
Corcept Therapeutics (CORT) Up 6.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?
by Zacks Equity Research
Investors in Corcept Therapeutics (CORT) need to pay close attention to the stock based on moves in the options market lately.
Why Is Corcept Therapeutics (CORT) Up 5.3% Since Its Last Earnings Report?
by Zacks Equity Research
Corcept Therapeutics (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Plans Korlym Label Expansion, Pipeline in Progress
by Zacks Equity Research
Corcept (CORT) is currently working on developing Korlym for additional indications. It also remains focused at the development of its pipeline progress.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.
Achaogen's NDA for Plazomicin Gets Priority Review From FDA
by Zacks Equity Research
Achaogen's (AKAO) NDA for its urinary tract infections candidate, plazomicin, gets FDA's priority review.
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now
by Zacks Equity Research
Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.
TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise
by Zacks Equity Research
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.